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Abstract  18 
Intravenous delivery of adenoviruses is the optimal route for many gene therapy applications. Once 19 
in the blood, coagulation factor X (FX) binds to the adenovirus capsid and protects the virion from 20 
natural antibody and classical complement-mediated neutralisation in mice. However, to date no 21 
studies have examined the relevance of this FX/viral immune protective mechanism in human 22 
samples. In this study we assessed the effects of blocking FX on adenovirus type 5 (Ad5) activity in 23 
the presence of human serum. FX prevented human IgM binding directly to the virus. In individual 24 
human sera samples (n=25), approximately half of those screened inhibited adenovirus transduction 25 
only when the Ad5:FX interaction was blocked, demonstrating that FX protected the virus from 26 
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neutralising components in a large proportion of human sera. In contrast, the remainder of sera 27 
tested had no inhibitory effects on Ad5 transduction and FX armament was not required for 28 
effective gene transfer. In human sera in which FX had a protective role, Ad5 induced lower levels of 29 
complement activation in the presence of FX. We therefore demonstrate for the first time the 30 
importance of Ad:FX protection in human samples and highlight subject variability and species-31 
specific differences as key considerations for adenoviral gene therapy. 32 
  33 
Introduction 34 
Adenovirus (Ad), a double stranded non-enveloped DNA virus, is the most frequently employed 35 
vector in gene therapy clinical trials. The majority of the research into this large family of viruses, 36 
composed of over 65 different human types, has focused on species C Ad type 5 (Ad5). Whilst Ad5 37 
has been shown to be relatively safe in the thousands of patients treated worldwide to date, efficacy 38 
following intravenous (i.v.) delivery has been limited. This is largely as a result of the off target host 39 
interactions endured by the virus once it comes into contact with the bloodstream. Therefore, 40 
understanding the behaviour of Ads upon exposure to blood is pivotal to their successful 41 
employment in systemic gene therapy and oncolytic virotherapy applications.  42 
Over the last decade, Ad5 interactions with host circulatory components has been the subject of 43 
extensive investigation (1-3). Several studies have examined the involvement of coagulation factor X 44 
(FX) in determining Ad5 tropism and immunogenicity in vivo (4, 5). Upon contact with blood, the FX 45 
Gla domain binds directly to the adenoviral hexon protein within its hypervariable regions (HVR5 and 46 
HVR7), and facilitates attachment to heparan sulphate proteoglycan (HSPG) receptors on the cell 47 
surface of hepatocytes (4, 6, 7). Whilst FX engagement of HSPGs has been proposed to mediate liver 48 
gene transfer, a recent study using mice lacking functional receptors has indicated that hepatocyte 49 
heparan sulphate is not essential for Ad5 liver transduction in mice (8). FX coating of the Ad5 hexon 50 
also has a key role in preventing the virus being recognised by murine natural antibodies, averting 51 
activation and attack by the classical complement system (2). Inclusion of Ad5-derived HVRs (HVR1-3 52 
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and 5-7) into a native non FX-binding virus, Ad type 26, sensitised this virus to immune recognition 53 
leading to neutralisation in vitro and in vivo, and directed the virus to the liver following i.v. delivery 54 
in mice (9). Whilst the aforementioned studies indicate the protective benefits of the FX interaction 55 
for Ad5 infection, other work details the processes by which FX binding to the virus induces nuclear 56 
factor κB-dependant inflammatory responses following systemic  vector administration in mice and 57 
heightens this arm of the host innate immunity (10). Evidently FX binding to Ad5 permits important 58 
immune modulatory functions in mice, however dramatically less is known about these mechanisms 59 
in humans. Notably, one recent study demonstrated that in contrast to murine FX binding to Ad5 60 
and triggering Toll-like receptor 4 (TLR4) mediated responses on mouse mononuclear cells, human 61 
FX was incapable of activating primary human macrophages, indicating species specific events and 62 
highlighting the importance of using human samples for research (11). 63 
 64 
Major strides have been made in understanding the mediators of viral biodistribution, cellular 65 
receptor binding profiles and innate immune responses following virus i.v. administration in vivo. 66 
However the majority of this work has relied heavily on small animal models, predominantly mice 67 
and unfortunately these studies can only provide limited information in terms of human 68 
translational relevance. The ability of FX to prevent Ad5 neutralisation by natural IgM antibodies and 69 
classical complement in mice has been detailed (2, 9), however no data describing the significance of 70 
this pathway in humans has yet been described. In the current study, we investigate the importance 71 
of FX immune protection of Ad vectors and host inhibitory mechanisms in human sera and highlight 72 
the relevance to gene therapy and the heterogeneity in responses in human samples. 73 
 74 
Results and Discussion 75 
Human FX interferes with direct binding of purified human IgM to Ad5 76 
The ability of FX to bind to the Ad5 HVRs, thereby preventing recognition and attack by murine 77 
natural antibodies and complement in mice has been documented. In order to study the importance 78 
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of this pathway in humans we began by investigating whether human IgM (hIgM) bound to Ad5 79 
directly and if this was influenced by human FX. We incubated purified hIgM with Alexa Fluor 532 80 
labelled Ad5 or the FX-binding deficient version Ad5T* (point mutations within the hexon HVR5 and 81 
HVR7 (12)) in the absence or presence of FX and analysed alterations in virus particle size using the 82 
NanoSight LM14 (NanoSight, UK). Binding of the free proteins to the fluorescently labelled virus 83 
particles correlates directly with an increase in size. The NanoSight LM14 and associated NTA 84 
software enables visualisation of nanoparticles in solution, robust particle-by-particle size 85 
measurements and quantification based on principles of Brownian motion and fluorescence light 86 
scattering (13). The lower size detection limit for the NanoSight LM14 is 10 nm, and whilst a hIgM 87 
pentamer is ~30 nm, FX is 9 nm and thus not detectable via this method (13, 14). A significant 88 
increase in particle size (~35 nm) was observed in the presence of hIgM, demonstrating a direct 89 
interaction with Ad5 (Figure 1A). Importantly, this interaction was inhibited when Ad5 was co-90 
incubated with FX, showing the ability of FX to hinder direct binding of hIgM to Ad5. hIgM also 91 
bound the non-FX-binder Ad5T*(Figure 1A), demonstrating that the amino acid residues of the virus 92 
responsible for interacting with FX are not required for the hIgM:Ad5 interaction, and as expected 93 
this was unaffected by FX. FX did not interfere with the binding of purified hIgG to Ad5 (Figure 1B). 94 
 95 
FX shielding of Ad5 and heterogeneity in human samples 96 
Next we investigated whether hIgM and complement components neutralised Ad5 in the absence of 97 
FX in whole human sera. A panel of 25 human sera, previously identified in our lab as having low 98 
levels of pre-existing neutralising hIgG antibodies (NAbs) to Ad5 (data not shown and some serum 99 
samples identified by Parker et al. 2009 and renumbered for this study) (15), were tested for effects 100 
on viral transduction in vitro in the absence or presence of FX. Xbp binds to the FX Gla domain and 101 
inhibits it’s interaction with the virus (1). Due to the presence of endogenous coagulation factors in 102 
the human sera, several samples enhanced Ad5 cellular transduction, an effect significantly reduced 103 
by Xbp (Figure 2A and B). The extent to which FX enhanced Ad5 transduction varied, and this can be 104 
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the result of differences in the endogenous concentrations of FX across the human subsets following 105 
blood clotting and serum production, and due to altering levels of NAbs. Of the 25 sera examined, in 106 
14 samples (56%) Xbp decreased Ad5 transgene expression to levels significantly below both media 107 
controls and serum alone (-Xbp) in A549 cells (Figure 2A). This demonstrated that without the FX 108 
protective coat the virus is neutralised by these sera. Importantly, in the remainder of human 109 
samples (44%) Xbp did not decrease Ad5 transduction compared to controls or incubation with 110 
serum alone, demonstrating that FX was not required for basal transduction under these conditions. 111 
Similar results were observed using SKOV3 cells, although there were some differences amongst the 112 
cell lines (4 of the 25 sera caused significant neutralisation compared to media controls and serum 113 
alone in only one cell type) (Figure 2B). Previous studies in mice have shown the ability of IgM to 114 
inhibit Ad5 gene transfer is directly related to the antibody titer, with the concentration of murine 115 
IgM negatively correlating with transduction (16). Variations in the levels of an individual’s natural 116 
antibodies may also contribute to differences shown here amongst our human sera samples. 117 
 118 
Species variation in FX:Ad5 protective requirements 119 
FX binding to Ad5 has been documented to protect the virus from immune neutralisation in mouse, 120 
guinea pig and rat sera samples in vitro (2, 9). Therefore, we performed a direct comparison 121 
between mouse sera and representative human sera (pooled sera samples #17, 22, 24 (refer to 122 
Figure 2A and B) in which FX did not have a protective role. In stark contrast to mouse sera, in the 123 
absence of FX we detected no inhibition by human sera and transduction was equivalent to the 124 
media controls (Figure 2C). Likewise Ad5T* transduction was not affected, again in contrast to the 125 
mouse sera. Taken together these data indicate that FX binding is not necessary to shield the virus 126 
from neutralisation in all human sera. 127 
 128 
FX prevents binding of sera components to Ad5 in a subset of human samples 129 
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We next investigated whether FX coating Ad5 was preventing recognition and direct binding of 130 
components in the whole human sera, to the viral capsid. We divided our serum samples into two 131 
subsets, those in which FX was required to protect the virus from neutralisation (group A) and those 132 
in which FX protection was not necessary for cellular transduction (Figure 2). Representative samples 133 
from each subset were incubated with Ad5 or Ad5T* in the absence or presence of Xbp and virus 134 
particle size was measured using the NanoSight LM14. There was a significant shift in Ad5 (Figure 3A 135 
and 3B) and Ad5T*(Figure 3C) particle size following incubation with sera from either group 136 
indicative of interactions with serum composites. These sera represent a heterogeneous population 137 
and some possess low levels of hIgG NAbs capable of binding the virus regardless of FX (Figure 2A 138 
and 2B). However only in the presence of group A sera, did Xbp result in a significant increase in Ad5 139 
particle size compared to incubation with sera alone (Figure 3A). This is indicative of binding of Ad5 140 
by hIgM and classical complement components in the absence of FX.  141 
 142 
FX influences Ad5 induction of the human classical complement pathway 143 
We next studied the early signalling effects of hIgM binding to the virus and the activation of 144 
complement pathways. C1q is the recognition component of the classical complement cascade 145 
which can bind IgG or IgM leading to the formation of C4b2a convertase, which cleaves C3 to 146 
generate C3a (17). C3a is very short lived and is rapidly cleaved in serum to the more stable product 147 
C3a-desArg, hence C3a-desArg is commonly used as a measure of complement activation. We 148 
observed increased levels of C3a-desArg in both human sera with high and low pre-existing NAbs 149 
(source of serum samples Parker et al. 2009 (15)) following incubation with Ad5, and this was further 150 
significantly increased by adding Xbp (Figure 4A, Supplementary Figure 1). The enhanced C3-desArg 151 
signal in the absence of FX versus its presence, suggests the ability of Ad5 to induce C3-desArg is not 152 
solely reliant on FX, however FX coating does impact upon the extent of complement-induced 153 
immunogenicity. In FX-depleted plasma Ad5 caused comparable levels of C3a-desArg regardless of 154 
Xbp (Figure 4B). C3a and C3a-desArg are common components of classical, lectin and alternative 155 
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complement pathways, whilst C1q is selectively involved in the classical system  (18). In human 156 
serum devoid of C1q no significant increase in C3-desArg was observed with Ad5 in the presence or 157 
absence of FX (Figure 4C). These data thereby indicate C1q-mediated C3 activation (i.e. classical 158 
complement) occurs in the presence of FX, but the levels of C3a-desArg induction is significantly 159 
increased when FX is absent, in the human sera samples tested. This suggests the human pathway is 160 
more complex than that observed in mice, in which no C3a activation occurs in the absence of FX (2, 161 
9), and having no prior exposure to Ad5 the animals contain no pre-existing NAbs. 162 
 163 
To conclude, this work shows for the first time that human FX binding to Ad5 shields the virus 164 
against neutralising human serum. However, we find there is a high level of heterogeneity amongst 165 
individual human samples in their response to Ad5 in the absence of FX, and viral coating by the 166 
coagulation factor is not always necessary for gene transfer. This is in contrast to mice, in which FX 167 
armament was essential for virus transduction in all immunocompetent models examined. 168 
Additionally, we find that antibody-mediated classical complement effects on Ad5 are more complex 169 
than that previously suggested by small animal model studies, in which there is no triggering of 170 
complement pathways when FX is present. This work highlights the benefits of employing 171 
translationally relevant experimental settings and human samples to investigate viral and host 172 
mechanisms. These data indicate the importance of screening patient antibody profiles prior to Ad5-173 
mediated gene therapy, as it will be fundamental in deciphering the response to treatment.  174 
 175 
Materials and Methods 176 
Cell lines and viruses 177 
Human embryonic kidney HEK293 cells were cultured in Dulbecco modified Eagle medium (DMEM; 178 
Invitrogen, Paisley, UK). Human ovarian carcinoma SKOV3 and lung carcinoma A549 cells (National 179 
Institutes of Health) were cultured in RPMI-1640 media (Invitrogen). Media was supplemented with 180 
2 mM L-glutamine and 10% FCS. Cells were maintained at 37°C and 5% CO2. Ad5 and Ad5T* 181 
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containing mutations within HVR5 (T270P and E271G) and HVR7 (I421G, T423N, E424S, L426Y, and 182 
E451Q) were described previously (12). 183 
 184 
Fluorescent labelling of Ad particles 185 
Ad5 and Ad5T* were fluorescently labelled using an Alexa Fluor 532 protein labelling kit according to 186 
the manufacturer's instructions (Invitrogen, Paisley, UK). To remove any free label the viruses were 187 
dialysed overnight using 10,000 molecular weight cut off slide-a-lyzer cassettes (Perbio Science, 188 
Cramlington, UK) in 100 mM Tris and 50 mM EDTA. Fluorescent dye labelling efficiency was assessed 189 
using the ‘proteins and labels’ function on the Nanodrop-1000 spectrophotometer. 190 
 191 
NanoSight LM14 particle size tracking 192 
Alexa Fluor 532 labelled Ad5 or Ad5T* vectors (1x109 vp) were incubated at room temperature for 193 
90 min in PBS (10 µl final volume) with human serum -/+ 40 µg/ml Xbp or with physiologically 194 
relevant concentrations of purified human IgM (100 µg/ml) or human IgG (10 µg/ml) -/+ 5 µg/ml 195 
human FX. Purified human blood coagulation factor X (FX) was purchased from Cambridge 196 
Biosciences (Cambridge, UK).  Samples were then diluted in 1.5 mL PBS, 1 ml of the sample was 197 
injected into the Nanosight LM14 (NanoSight UK) and fluorescent virus particle sizes were tracked. 198 
Results show representative data from a minimum of three separate experiments with ~300-700 199 
completed tracks. 200 
 201 
Serum neutralisation assays 202 
A549 and SKOV3 cells were plated in a 96 well format (1x104 cells/well) and incubated overnight at 203 
37˚C. Human sera or murine sera from C57BL/6 mice were diluted to 80-90% in RPMI-1640 and 204 
incubated with 2x1010 vp/ml Ad5 or Ad5T* in a final volume of 50 µl. Xbp was added to test samples 205 
at 40 µg/ml to deplete the FX in the serum prior to the addition of virus. Controls were Ad alone in 206 
serum-free medium. Viruses were incubated with serum or medium for 30 min at 37°C. Mixtures 207 
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were diluted 200-fold in serum-free medium. Cells were rinsed and 100 µl of diluted vector (1000 208 
vp/well) was added to triplicate wells for 2 h at 37°C. The inoculum was then replaced with medium 209 
containing 2% heat-inactivated FBS.  After ~16 h, cells were rinsed with PBS and harvested for 210 
determination of luciferase transgene expression and protein content using the BCA assay. C3a-211 
desArg ELISAs were performed in order to ensure an intact complement system in sera from all 212 
groups. 213 
 214 
C3a-desArg ELISA 215 
Virus (5x1010 vp/ml) was incubated with 50 µl of human serum, FX depleted plasma (Cambridge 216 
Bioscience, UK) or C1q depleted serum (Quidel, San Diego, USA) -/+ 40 µg/ml Xbp for 90 min at 37°C, 217 
then 10 mM EDTA was added. Samples were frozen at –80 °C until evaluation in a human C3a-218 
desArg ELISA as previously described (19).  219 
 220 
Statistical data analysis 221 
Significance was calculated using two sample, two tailed student’s t-tests or where described by one 222 
way ANOVA with Tukey’s post-hoc test. P values of <0.05 were considered to be significant. Results 223 
presented are representative data from a minimum of three separate experiments with at least 224 
three experimental replicates per group. All error bars represent SEM. 225 
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 279 
Figure Legends 280 
Figure 1. Ad5 binds human IgM in a FX dependent manner. Alexa Fluor 532 labelled Ad5 or Ad5T* 281 
vectors (1x109 vp) were incubated at room temperature for 90 min in PBS (10 µL final volume) with 282 
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physiologically relevant concentrations of (A) human IgM (100 µg/mL) or (B) human IgG (10 µg/mL) 283 
in the presence or absence of human FX (5 µg), then diluted in 1.5 mL PBS and injected into the 284 
Nanosight. Each result is representative data from a minimum of three separate experiments with 285 
~300 completed tracks. Mean ± SEM compared by one way ANOVA, Tukey’s post-hoc test, *p<0.05 286 
vs. matched control or hIgM conditions. 287 
 288 
Figure 2. Screening human sera samples to investigate a protective role of FX. (A) A549 and (B) 289 
SKOV3 cells: Ad5 (2x1010 vp/mL) were incubated with media (control) or 25 different human sera -/+ 290 
40 µg/mL Xbp for 30 min at 37°C. (C) SKOV3 cells: Ad5 or Ad5T* (2x1010 vp/mL) was incubated with 291 
media (CON), human or mouse serum -/+ 40 µg/mL Xbp for 30 min at 37°C. Representative human 292 
serum samples which did not show a dependence on FX for protection (pooled sera #17, 22, 24) 293 
were used in this experiment. Virus suspensions were diluted 200-fold in serum-free media and 100 294 
µL added to cells for 2 h at 37°C, then replaced with media with 2% FCS. Transgene expression was 295 
quantified ~16 h post-transduction and relative light units (RLU) were normalized to mg total 296 
protein. Graphs show transduction as a percentage of control (Ad transduction with media). Media 297 
control (*p<0.05) or matched serum – Xbp conditions (#p<0.05) versus serum + Xbp.  298 
 299 
Figure 3. Ad binding to human serum components. Alexa Fluor 532 labelled (A+B) Ad5 or (C) Ad5T* 300 
(1x109 virus particles) was incubated at room temperature for 90 minutes in human sera -/+ 40 301 
µg/mL Xbp (25 µl final volume). (A) Sera Group A = sensitive to neutralisation in the absence of FX 302 
(1x representative of this group, serum sample #5, shown here), (B) Group B = not sensitive to 303 
neutralisation in the absence of FX (1x representative of this group, serum sample #24 presented 304 
here). Samples were diluted in 1.5 mL PBS and injected into the Nanosight. Each result is 305 
representative data from minimum three separate experiments with ~700 completed tracks. Mean ± 306 
SEM compared by One way ANOVA, Tukey’s post-hoc test, *p<0.05 vs. matched control or serum – 307 
Xbp conditions. 308 
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 309 
Figure 4. Effects on human complement activation. Human sera was incubated with Ad (5x1010 310 
vp/mL) in the presence or absence of 40 μg/mL Xbp for 90 min at 37°C. (A) Human sera with high 311 
pre-existing neutralising IgG titres (high NAbs) and sera samples with low IgG titres which exhibited a 312 
dependence on FX for protection (low NAbs Group A), (B) FX-depleted human plasma (Quadratech 313 
Diagnostics, UK) and (C) C1q depleted human sera were used. C3a-desArg levels were quantified by 314 
ELISA. Graphs show transduction as a percentage of serum + PBS. *p < 0.05 vs. matched PBS or Ad5.  315 
 316 
